Functional connectivity between tumor region and resting-state networks as imaging biomarker for overall survival in recurrent gliomas diagnosed by O-(2-[(18)F]fluoroethyl)-l-tyrosine PET

肿瘤区域与静息态网络之间的功能连接作为O-(2-[(18)F]氟乙基)-L-酪氨酸PET诊断的复发性胶质瘤患者总生存期的影像学生物标志物

阅读:2

Abstract

BACKGROUND: Amino acid PET using the tracer O-(2-[(18)F]fluoroethyl)-l-tyrosine (FET) is one of the most reliable imaging methods for detecting glioma recurrence. Here, we hypothesized that functional MR connectivity between the metabolic active recurrent tumor region and resting-state networks of the brain could serve as a prognostic imaging biomarker for overall survival (OS). METHODS: The study included 82 patients (26-81 years; median Eastern Cooperative Oncology Group performance score, 0) with recurrent gliomas following therapy (WHO-CNS 2021 grade 4 glioblastoma, n = 57; grade 3 or 4 astrocytoma, n = 12; grade 2 or 3 oligodendroglioma, n = 13) diagnosed by FET PET simultaneously acquired with functional resting-state MR. Functional connectivity (FC) was assessed between tumor regions and 7 canonical resting-state networks. RESULTS: WHO tumor grade and IDH mutation status were strong predictors of OS after recurrence (P < .001). Overall FC between tumor regions and networks was highest in oligodendrogliomas and was inversely related to tumor grade (P = .031). FC between the tumor region and the dorsal attention network was associated with longer OS (HR, 0.88; 95%CI, 0.80-0.97; P = .007), and showed an independent association with OS (HR, 0.90; 95%CI, 0.81-0.99; P = .033) in a model including clinical factors, tumor volume and MGMT. In the glioblastoma subgroup, tumor volume and FC between the tumor and the visual network (HR, 0.90; 95%CI, 0.82-0.99, P = .031) were independent predictors of survival. CONCLUSIONS: Recurrent gliomas exhibit significant FC to resting-state networks of the brain. Besides tumor type and grade, high FC between the tumor and distinct networks could serve as independent prognostic factors for improved OS in these patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。